Implementation of a Molecular Diagnostic for Pediatric Acute Gastroenteritis: The FilmArray GI Panel IMPACT Study



Status:Completed
Conditions:Infectious Disease, Gastrointestinal
Therapuetic Areas:Gastroenterology, Immunology / Infectious Diseases
Healthy:No
Age Range:Any - 18
Updated:12/27/2017
Start Date:April 2015
End Date:August 2016

Use our guide to learn which trials are right for you!

BioFire Diagnostics, LLC (BioFire) has developed the FilmArray Gastrointestinal (GI) Panel, a
rapid, easy to use PCR-based in vitro diagnostic test for the identification of 22 common
microorganisms responsible for infectious gastroenteritis (http://filmarray.com/the-panels/)
from a stool specimen collected in Cary Blair enteric transport media. The test was made
available for sale in the US and EU following FDA clearance and CE marking in May, 2014.

The FilmArray GI Panel offers improvements over conventional laboratory testing which
include: reduced turnaround time from specimen to result, reduced laboratory labor costs,
increased sensitivity and specificity relative to current clinical reference methods, and
larger breadth of organism identification than is available using standard methods. Because
of these attributes, the results from this test have the potential to enable clinicians to
more accurately diagnose and treat GI illness in a reduced time frame.

Collaborators at the University of Utah, Brown University/Lifespan, and BioFire Diagnostics
have designed a study to evaluate health outcomes of pediatric subjects presenting to
emergency departments with GI illness before and after establishing the FilmArray GI Panel as
the standard of care method for stool pathogen analysis. It is hypothesized that the rapid (~
1 hour turnaround time), sensitive, specific, and comprehensive results provided by the
FilmArray GI Panel will allow clinicians to more rapidly diagnose GI illness, initiate
appropriate therapy and provide guidance when compared to the pre-implementation period.


Inclusion Criteria:

- Children (<18 years) presenting to the ED or onsite urgent care center with symptoms
of gastroenteritis (e.g. diarrhea, vomiting, nausea, etc.)

- Duration of symptoms at least 24 hours but < 14 days

- Able to provide stool specimen at time of enrollment or within the next two calendar
days

- Parent or guardian able to provide permission and subject able to provide assent, if
appropriate

Exclusion Criteria:

- Undefined onset of illness or symptoms for ≥14 days

- Unable to complete questionnaire or give informed consent because of language barrier

- Those unable to provide stool specimen at time of enrollment or within two calendar
days

- Previous enrollment in this study
We found this trial at
5
sites
2401 Gillham Rd
Kansas City, Missouri 64108
(816) 234-3000
Principal Investigator: Rangraj Selvarangav, BVSc, PhD, D(ABMM)
Phone: 816.234.3000
Children's Mercy Hospital Children's Mercy Hospitals and Clinics continues redefining pediatric medicine throughout the Midwest...
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
700 Childrens Drive
Columbus, Ohio 43205
(616) 722-2000
Principal Investigator: Daniel Cohen, MD
Phone: 614-722-2000
Nationwide Children's Hospital At Nationwide Children’s, we are creating the future of pediatric health care....
?
mi
from
Columbus, OH
Click here to add this to my saved trials
4650 Sunset Blvd
Los Angeles, California 90027
 (323) 660-2450
Principal Investigator: Jennifer Dien Bard, PhD, FCCM, D(ABMM)
Phone: (323) 660-2450
Childrens Hospital Los Angeles Children's Hospital Los Angeles is a 501(c)(3) nonprofit hospital for pediatric...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Providence, Rhode Island 02903
Principal Investigator: Kimberle Chapin, MD
Phone: 401-444-3500
?
mi
from
Providence, RI
Click here to add this to my saved trials
Salt Lake City, Utah 84132
Principal Investigator: Andy Pavia, MD
Phone: 801-662-1000
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials